Clinical Trial Update: Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen at Least 2nd Line in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial compares capecitabine versus endocrine therapy as a maintenance regimen after second-line treatment in hormone receptor-positive, HE…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Endocrinotherapy

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: Breast Cancer | Phase 2 | Status: UNKNOWN